3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
14
Non-Muscle Invasive Bladder Neoplasms
10
Colorectal Neoplasms
7
Appendiceal Neoplasms
6
Anus Neoplasms
6
Peritoneal Neoplasms
5
Carcinoma, Transitional Cell
5
Stomach Neoplasms
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Peritoneal Diseases
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Necrosis
1
Nasopharyngeal Carcinoma
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Interventions
pembrolizumab
2
darolutamide
2
relatlimab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Surveys and Questionnaires
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
Mitomycin
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled